Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells

Seminars in Oncology

Volumn 43, Issue 2, 2016, Pages 291-299

  Fraietta, Joseph A ^a   Schwab, Robert D ^a   Maus, Marcela V ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Building 149 ^*  (United States)

Author keywords

CAR; CLL; Immunotherapy; Leukemia; T cell

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INDUCIBLE T CELL COSTIMULATOR; TISAGENLECLEUCEL T; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; APLASIA; B CELL APLASIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; CHIMERIC ANTIGEN RECEPTOR T CELL; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE SYNDROME; GENETIC ENGINEERING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFUSION RELATED REACTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSIENT EXPRESSION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR LYSIS SYNDROME; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 84961116781     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.02.006     Document Type: Review

References (124)

1. S. Bottcher Paving the road to MRD-guided treatment in CLL Blood 123 24 2014 3683 3684
2. P. Dreger, J. Schetelig, N. Andersen, and et al. Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents? Blood 124 26 2014 3841 3849
3. J.C. Byrd, R.R. Furman, S.E. Coutre, and et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 1 2013 32 42
4. R.R. Furman, J.P. Sharman, S.E. Coutre, and et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 11 2014 997 1007
5. T. Zenz, S. Habe, T. Denzel, and et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial Blood 114 13 2009 2589 2597
6. J.A. Jones, and J.C. Byrd How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123 10 2014 1455 1460
7. A. Aalipour, and R.H. Advani Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: Focus on ibrutinib Ther Adv Hematol 5 4 2014 121 133
8. S. Bottcher, M. Ritgen, and P. Dreger Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies Blood Rev 25 2 2011 91 96
9. S.M. Jaglowski Transplant for CLL: Still an option? Blood 124 26 2014 3835 3836
10. M. Kalos, B.L. Levine, D.L. Porter, and et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 95 2011 95ra73
11. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 8 2011 725 733
12. R.J. Brentjens, I. Riviere, J.H. Park, and et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 18 2011 4817 4828
13. J.N. Kochenderfer, M.E. Dudley, S.A. Feldman, and et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 12 2012 2709 2720
14. J.N. Kochenderfer, W.H. Wilson, J.E. Janik, and et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 20 2010 4099 4102
15. B. Savoldo, C.A. Ramos, E. Liu, and et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients J Clin Invest 121 5 2011 1822 1826
16. Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. 55th American Society of Hematology Meeting 2014;12014;1982.
17. Porter D, Lacey SF, Hwang WT, et al. Cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) CLL. 55th American Society of Hematology Meeting 2014;1983.
18. M.V. Maus, J.A. Fraietta, B.L. Levine, M. Kalos, Y. Zhao, and C.H. June Adoptive immunotherapy for cancer or viruses Annu Rev Immunol 32 2014 189 225
19. D.L. Porter, W.T. Hwang, N.V. Frey, and et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Sci Transl Med 7 303 2015 303ra139
20. S.L. Maude, N. Frey, P.A. Shaw, and et al. Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 16 2014 1507 1517
21. T. Brocker, and K. Karjalainen Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors Adv Immunol 68 1998 257 269
22. M. Sadelain, I. Riviere, and R. Brentjens Targeting tumours with genetically enhanced T lymphocytes Nat Rev Cancer 3 1 2003 35 45
23. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci USA 86 24 1989 10024 10028
24. J.H. Pinthus, T. Waks, K. Kaufman-Francis, and et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes Cancer Res 63 10 2003 2470 2476
25. B.P. Mullaney, and M.G. Pallavicini Protein-protein interactions in hematology and phage display Exp Hematol 29 10 2001 1136 1146
26. T. Brocker Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells Blood 96 5 2000 1999 2001
27. + T cells in the absence of exogenous feeder cells J Immunol 159 12 1997 5921 5930
28. M.V. Maus, A.K. Thomas, D.G. Leonard, and et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat Biotechnol 20 2 2002 143 148
29. S.A. Grupp, M. Kalos, D. Barrett, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 16 2013 1509 1518
30. C.M. Paulos, C. Carpenito, G. Plesa, and et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells Sci Transl Med 2 55 2010 55ra78
31. S. Guedan, X. Chen, A. Madar, and et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells Blood 124 7 2014 1070 1080
32. A.D. Miller, and G.J. Rosman Improved retroviral vectors for gene transfer and expression Biotechniques 7 9 1989 980 982
33. L. Naldini, U. Blomer, P. Gallay, and et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 5259 1996 263 267
34. Y. Zhao, E. Moon, C. Carpenito, and et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor Cancer Res 70 22 2010 9053 9061
35. Porter DL, Hwang W, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139
36. J.C. Riches, J.K. Davies, F. McClanahan, and et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production Blood 121 9 2013 1612 1621
37. + T-cell memory in tumor immunology and immunotherapy Immunol Rev 211 2006 214 224
38. J.G. Crompton, D. Clever, R. Vizcardo, M. Rao, and N.P. Restifo Reprogramming antitumor immunity Trends Immunol 35 4 2014 178 185
39. + T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 1 2008 294 305
40. W. Dummer, A.G. Niethammer, R. Baccala, and et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity J Clin Invest 110 2 2002 185 192
41. L. Gattinoni, E. Lugli, Y. Ji, and et al. A human memory T cell subset with stem cell-like properties Nat Med 17 10 2011 1290 1297
42. + memory stem cells Nat Med 15 7 2009 808 813
43. + memory stem cells in graft-versus-host disease Nat Med 11 12 2005 1299 1305
44. E. Lugli, M.H. Dominguez, L. Gattinoni, and et al. Superior T memory stem cell persistence supports long-lived T cell memory J Clin Invest 123 2 2013 594 599
45. R. Ramesh, L. Kozhaya, K. McKevitt, and et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids J Exp Med 211 1 2014 89 104
46. S. Phuphanich, C.J. Wheeler, J.D. Rudnick, and et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma Cancer Immunol Immunother 62 1 2013 125 135
47. M.W. Frohlich Sipuleucel-T for the treatment of advanced prostate cancer Semin Oncol 39 3 2012 245 252
48. C.J. Wheeler, and K.L. Black DCVax-Brain and DC vaccines in the treatment of GBM Expert Opin Investig Drugs 18 4 2009 509 519
49. M. Fishman A changing world for DCvax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer Expert Opin Biol Ther 9 12 2009 1565 1575
50. P. Guermonprez, J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena Antigen presentation and T cell stimulation by dendritic cells Annu Rev Immunol 20 2002 621 667
51. L. Fong, and E.G. Engleman Dendritic cells in cancer immunotherapy Annu Rev Immunol 18 2000 245 273
52. F.O. Nestle, J. Banchereau, and D. Hart Dendritic cells: On the move from bench to bedside Nat Med 7 7 2001 761 765
53. C. Renner, S. Ohnesorge, G. Held, and et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28 Blood 88 1 1996 236 241
54. +) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res 61 12 2001 4766 4772
55. M. Bonyhadi, M. Frohlich, A. Rasmussen, and et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia J Immunol 174 4 2005 2366 2375
56. P. Patten, S. Devereux, A. Buggins, M. Bonyhadi, M. Frohlich, and R.J. Berenson Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia J Immunol 174 11 2005 6562 6563
57. M. Oelke, M.V. Maus, D. Didiano, C.H. June, A. Mackensen, and J.P. Schneck Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells Nat Med 9 5 2003 619 624
58. M.M. Suhoski, T.N. Golovina, N.A. Aqui, and et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules Mol Ther 15 5 2007 981 988
59. S.G. Deeks, B. Wagner, P.A. Anton, and et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy Mol Ther 5 6 2002 788 797
60. M.H. Kershaw, J.A. Westwood, L.L. Parker, and et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 20 Pt 1 2006 6106 6115
61. J.R. Park, D.L. Digiusto, M. Slovak, and et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol Ther 15 4 2007 825 833
62. P. Christopoulos, D. Pfeifer, K. Bartholome, and et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL Blood 117 14 2011 3836 3846
63. E.A. Ranheim, M.J. Cantwell, and T.J. Kipps Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells Blood 85 12 1995 3556 3565
64. E.A. Ranheim, and T.J. Kipps Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal J Exp Med. 177 4 1993 925 935
65. J.C. Riches, A.G. Ramsay, and J.G. Gribben T-cell function in chronic lymphocytic leukaemia Semin Cancer Biol 20 6 2010 431 438
66. L.E. Van den Hove, S.W. Van Gool, P. Vandenberghe, and et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules Leukemia 11 4 1997 572 580
67. M.J. Yellin, J. Sinning, L.R. Covey, and et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity J Immunol. 153 2 1994 666 674
68. A. Rissiek, C. Schulze, U. Bacher, and et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia Int J Cancer 135 10 2014 2370 2379
69. D. Bagnara, M.S. Kaufman, C. Calissano, and et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease Blood 117 20 2011 5463 5472
70. J.A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio The microenvironment in mature B-cell malignancies: A target for new treatment strategies Blood 114 16 2009 3367 3375
71. G. D'Arena, F. D'Auria, V. Simeon, and et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia Am J Hematol 87 6 2012 628 631
72. G. D'Arena, L. Laurenti, M.M. Minervini, and et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease Leuk Res 35 3 2011 363 368
73. G. D'Arena, G. Rossi, M.M. Minervini, and et al. Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis Int J Immunopathol Pharmacol 24 4 2011 915 923
74. L. Weiss, T. Melchardt, A. Egle, C. Grabmer, R. Greil, and I. Tinhofer Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia Cancer 117 10 2011 2163 2169
75. F. Dazzi, E. D'Andrea, G. Biasi, and et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens Clin Immunol Immunopathol. 75 1 1995 26 32
76. M. Aguilar-Santelises, D. Gigliotti, L.M. Osorio, A.D. Santiago, H. Mellstedt, and M. Jondal Cytokine expression in B-CLL in relation to disease progression and in vitro activation Med Oncol. 16 4 1999 289 295
77. L. Fayad, M.J. Keating, J.M. Reuben, and et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome Blood 97 1 2001 256 263
78. S. Scrivener, R.V. Goddard, E.R. Kaminski, and A.G. Prentice Abnormal T-cell function in B-cell chronic lymphocytic leukaemia Leuk Lymphoma 44 3 2003 383 389
79. M. Cantwell, T. Hua, J. Pappas, and T.J. Kipps Acquired CD40-ligand deficiency in chronic lymphocytic leukemia Nat Med 3 9 1997 984 989
80. A. Kretz-Rommel, F. Qin, N. Dakappagari, and et al. CD200 expression on tumor cells suppresses antitumor immunity: New approaches to cancer immunotherapy J Immunol 178 9 2007 5595 5605
81. C.P. Pallasch, S. Ulbrich, R. Brinker, M. Hallek, R.A. Uger, and C.M. Wendtner Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade Leuk Res 33 3 2009 460 464
82. + T-cell function is not impaired in chronic lymphocytic leukemia Blood 123 5 2014 717 724
83. A.G. Ramsay, A.J. Johnson, A.M. Lee, and et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug J Clin Invest 118 7 2008 2427 2437
84. A.G. Ramsay, A.J. Clear, R. Fatah, and J.G. Gribben Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer Blood 120 7 2012 1412 1421
85. +) T-cell population Cytometry 42 3 2000 188 195
86. + T cell subsets in chronic lymphocytic leukemia J Immunol. 158 3 1997 1482 1489
87. + T lymphocytes depend on infection with CMV J Immunol 170 8 2003 4342 4348
88. A. Rosen, F. Murray, C. Evaldsson, and R. Rosenquist Antigens in chronic lymphocytic leukemia - implications for cell origin and leukemogenesis Semin Cancer Biol 20 6 2010 400 409
89. M. Duhren-von Minden, R. Ubelhart, D. Schneider, and et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling Nature 489 7415 2012 309 312
90. + T cells for adoptive immunotherapy Blood 111 11 2008 5326 5333
91. B.L. Levine, and C.H. June Perspective: Assembly line immunotherapy Nature 498 7455 2013 S17
92. D.M. Barrett, N. Singh, X. Liu, and et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy Cytotherapy 16 5 2014 619 630
93. + T cells Proc Natl Acad Sci USA 101 7 2004 1969 1974
94. + T cells Ann Hematol 89 2 2010 115 120
95. N. Cieri, B. Camisa, F. Cocchiarella, and et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors Blood 121 4 2013 573 584
96. H. Singh, M.J. Figliola, M.J. Dawson, and et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies Cancer Res 71 10 2011 3516 3527
97. Y. Li, M. Bleakley, and C. Yee IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response J Immunol 175 4 2005 2261 2269
98. D. Eaton, D.E. Gilham, A. O'Neill, and R.E. Hawkins Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions Gene Ther 9 8 2002 527 535
99. J.A. Fraietta, Y.M. Mueller, G. Yang, and et al. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection PLoS Pathog 9 10 2013 e1003658
100. N. Rufer, M. Migliaccio, J. Antonchuk, R.K. Humphries, E. Roosnek, and P.M. Lansdorp Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential Blood 98 3 2001 597 603
101. M. Lotz, E. Ranheim, and T.J. Kipps Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells J Exp Med. 179 3 1994 999 1004
102. C.M. Bollard, C. Rossig, M.J. Calonge, and et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity Blood 99 9 2002 3179 3187
103. C. Liu, C.M. Lewis, Y. Lou, and et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo J Immunother 35 3 2012 276 282
104. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
105. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
106. A.K. Gopal, B.S. Kahl, S. de Vos, and et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma N Engl J Med 370 11 2014 1008 1018
107. J.A. Dubovsky, K.A. Beckwith, G. Natarajan, and et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Blood 122 15 2013 2539 2549
108. M.V. Maus, A.R. Haas, G.L. Beatty, and et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans Cancer Immunol Res 1 1 2013 26 31
109. S.L. Maude, D.T. Teachey, D.L. Porter, and S.A. Grupp CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Blood 125 26 2015 4017 4023
110. + T cells J Immunol 194 3 2014 911 920
111. M. Hudecek, M.T. Lupo-Stanghellini, P.L. Kosasih, and et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells Clin Cancer Res 19 12 2013 3153 3164
112. M. Hudecek, T.M. Schmitt, S. Baskar, and et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor Blood 116 22 2010 4532 4541
113. S. Gill, S.K. Tasian, M. Ruella, and et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells Blood 123 15 2014 2343 2354
114. A. Mardiros, C. Dos Santos, T. McDonald, and et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia Blood 122 18 2013 3138 3148
115. M. Casucci, B. Nicolis di Robilant, L. Falcone, and et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma Blood 122 20 2013 3461 3472
116. J. Scholler, T.L. Brady, G. Binder-Scholl, and et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Sci Transl Med 4 132 2012 132ra153
117. +-selected hematopoietic cell transplantation Blood 102 6 2003 2004 2013
118. M.E. Dudley, J.R. Wunderlich, J.C. Yang, and et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 10 2005 2346 2357
119. J.S. Miller, Y. Soignier, A. Panoskaltsis-Mortari, and et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 8 2005 3051 3057
120. +) T cell responses by regulating interferon signaling Nat Immunol 14 6 2013 593 602
121. + T cell responses to virus infection and cancer Immunity 38 4 2013 742 753
122. + T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic gammac cytokines Proc Natl Acad Sci USA 112 2 2014 476 481
123. A.P. Rapoport, E.A. Stadtmauer, N. Aqui, and et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells Clin Cancer Res 15 13 2009 4499 4507
124. S.A. Grupp, E.L. Prak, J. Boyer, and et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma Clin Cancer Res 18 24 2012 6732 6741